DiscoverCut the Chat Life Science InsiderInnovation, Execution, and Equity in RNA-Based Women’s Health
Innovation, Execution, and Equity in RNA-Based Women’s Health

Innovation, Execution, and Equity in RNA-Based Women’s Health

Update: 2025-08-15
Share

Description

In this episode, Seuss+ CEO and Co-Founder Sabine Hutchison sits down with Klaas Zuideveld, CEO of Versameb, to discuss the scientific, clinical, and societal implications of RNA-based therapies targeting stress urinary incontinence, a condition affecting hundreds of millions of women worldwide. Klaas shares his insights into Versameb’s lead program, VMB-100, and how their regenerative mRNA platform aims to transform women’s health by offering scalable, minimally invasive solutions. From novel anatomy discoveries and IND clearance to market misconceptions and funding barriers, this conversation unpacks the urgency, and opportunity of driving innovation in underserved therapeutic areas. Together, they explore why executional clarity and equity are essential for unlocking the future of RNA in clinical development.

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Innovation, Execution, and Equity in RNA-Based Women’s Health

Innovation, Execution, and Equity in RNA-Based Women’s Health